KDIGONephrology2024New Guideline
KDIGO Clinical Practice Guideline for CKD Evaluation, Management and Treatment 2024
Published by Kidney Disease: Improving Global Outcomes · 94 pages · Class I–II
Class ISGLT2i
2021 CKD-EPIeGFR equation
Class IIaFinerenone
Summary
Free previewComprehensive update to KDIGO CKD guidelines. SGLT2 inhibitors now Class I for CKD with or without diabetes to slow progression. Finerenone recommended in diabetic CKD. Updated GFR equations (2021 CKD-EPI without race coefficient) and revised staging criteria for cardiorenal syndrome.
CKDSGLT2iFinerenoneeGFRCardiorenal syndromeDiabetic nephropathy
Key Recommendations
Evidence Grading & Drug Doses
What's New vs Previous Version
Implementation & Clinical Pearls
Full guideline access requires an account
Create a free Prognia account to read the complete guideline — including all recommendations, evidence tables, drug dosing, and clinical pearls.
Full guideline text with all recommendations
Evidence grades (Class I/II/III, Level A/B/C)
AI-generated summary and clinical pearls
Auto-logged as CPD/CME activity
Free plan includes 10 guideline reads per day · No credit card required